Method and composition for the treatment of diabetes
First Claim
Patent Images
1. A composition for the treatment of diabetes mellitus comprising:
- (a) a therapeutic amount of an insulin sensitizer; and
(b) a therapeutic amount of an anti-diabetic agent.
1 Assignment
0 Petitions
Reexaminations
Accused Products
Abstract
This invention is directed to a novel method and composition for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance ["IGT"]and Type II). More specifically, this invention pertains to a novel method of treating diabetes mellitus by incorporating a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.
145 Citations
24 Claims
-
1. A composition for the treatment of diabetes mellitus comprising:
-
(a) a therapeutic amount of an insulin sensitizer; and (b) a therapeutic amount of an anti-diabetic agent. - View Dependent Claims (2, 3, 4, 15)
-
-
5. A composition for the treatment of diabetes mellitus in a mammal comprising:
-
(a) a therapeutically effective amount of an orally ingestible insulin which is formulated to withstand degradation by passage through the stomach and upper intestine of the mammal so that a therapeutically effective level of insulin reaches the bloodstream of the mammal; and
,(b) a therapeutically effective amount of one or more of a orally ingestible insulin sensitizer which withstands degradation by the stomach contents and upper intestinal tract of the mammal and reaches the bloodstream of the mammal and thereby sensitizes the cells of the mammal to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the orally ingested insulin required for a therapeutic dose. - View Dependent Claims (7, 9, 11, 13)
-
-
6. A composition for the treatment of diabetes mellitus comprising:
-
(a) a therapeutically effective amount of an injected insulin; and
,(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of injected insulin. - View Dependent Claims (8, 10, 12, 14)
-
- 16. A method for the treatment of diabetes mellitus comprising administering to a person afflicted with diabetes mellitus a therapeutic amount of an insulin sensitizer with a therapeutic amount of an anti-diabetic agent.
-
21. A method for the treatment of diabetes mellitus comprising administering to a person afflicted with diabetes mellitus a therapeutic amount of an insulin sensitizer with a therapeutic amount of an orally ingestible anti-diabetic agent, wherein
(1) the insulin sensitizer is selected from the group consisting of: - BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411, and wherein
(2) the anti-diabetic agent is selected from the group consisting of;
an orally ingestible insulin;
an injectible insulin;
a sulfonylurea;
a biguanide; and
an alpha-glucosidase inhibitor. - View Dependent Claims (22, 23, 24)
- BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411, and wherein
Specification